Sharemaestro Newsreel

ABCL|Abcellera Biologics Inc|Price:5.715|Chg%:+0.025

This article provides a comprehensive stock analysis of Abcellera Biologics Inc (ABCL) based on TradingKey's proprietary scoring system. ABCL's fundamentals are described as stable with high growth potential, and its valuation is considered fair within the Biotechnology & Medical Research industry. The report highlights …

Adaptive Biotechnologies Q2 Net Loss Widens Despite Revenue Growth; Stock Down

(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), a commercial-stage biotechnology company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss amid revenue growth. In addition, the company also provided an update on its full-year 2026 revenue outlook for …

Earnings call transcript: CareDx beats Q2 2026 estimates and lifts outlook

Fulgent Genetics (FLGT) Earnings Date and Reports 2026 $FLGT

CareDx, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CDNA) 2026-07-30

CareDx, Inc. (CDNA) reported impressive Q2 2026 earnings, significantly beating EPS and revenue expectations. The company saw a 59.5% beat on EPS with $0.37 against an estimated $0.23, and revenue reached $132 million, surpassing the $114 million estimate by 15.7%. This strong performance was …

CareDx (NASDAQ: CDNA) swings to profit, sells lab products unit and buys Naveris

CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates

ICON Public Limited Company 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ICLR) 2026-07-30

ICON reported strong Q1 2026 financial results, with gross bookings up 22% year-over-year and net business wins of $2.88 billion. The company reaffirmed its full-year 2026 guidance for revenue and adjusted diluted EPS, expecting modest sequential margin improvement. Strategic investments in central labs, oncology …

Earnings call transcript: ICON beats Q2 2026 estimates but shares slip premarket

ICON reported strong Q1 2026 financial results, with gross bookings up 22% year-over-year and net business wins of $2.88 billion. The company reaffirmed its full-year 2026 guidance for revenue and adjusted diluted EPS, expecting modest sequential margin improvement. Strategic investments in central labs, oncology …

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates

Fulgent Genetics (FLGT) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss

Mettler-Toledo (MTD) Q2 Earnings Surpass Estimates

Natera's second-quarter update follows market close Aug. 6

Is IDEXX Laboratories (IDXX) Fairly Valued After Its 2025 Corporate Responsibility Report?

Illumina (ILMN) Reports Q2 Earnings: What Key Metrics Have to Say

Illumina Fiscal Q2 Earnings, Revenue Rise; 2026 Guidance Revised

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 44.3% year on year to $335 million. The company's full-year revenue guidance of $1.35 billion at …

Is OPKO Health (OPK) A Bargain After Its Q2 Earnings And 52 Week High?

Thermo Fisher Scientific (TMO) Could Be 2% Undervalued After Q2 Earnings Beat

Revvity Inc (RVTY) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Revvity Inc (RVTY), noting its current risk score of 7.44 and its ranking within the Healthcare Equipment & Supplies industry. It details the company's beta value of 1.12, indicating higher volatility compared to the S&P 500. The …

Biotech Stocks Surge with Advanced Biomed Leading Gains

Advanced Biomed (ADVB) experienced a significant stock price surge of over 211% this week, driven by strong investor interest in its microfluidic technology despite not yet having commercial sales. Other biotech companies like Novocure (NVCR), Medpace (MEDP), and SciSparc (SPRC) also showed substantial gains …

ALEC|Alector Inc|Price:1.640|Chg%:+0.120

Alector Inc (ALEC) has received an overall TradingKey Stock Score of 5.79/10, indicating stable fundamentals and significant growth potential, although its valuation is considered fairly valued. Institutional ownership is very high, and analysts have recently rated the stock as "Hold" with a target price …

Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 3, 2026 - WGS

Levi & Korsinsky, LLP has issued a reminder to investors in GeneDx Holdings Corp. (NASDAQ: WGS) about a pending securities class action lawsuit. The lawsuit alleges that GeneDx management misled investors about deteriorating reimbursement rates and margin compression between April 16, 2025, and May …

Earnings Preview: Revvity to Report Financial Results Pre-market on August 04

This article announces that Revvity (NYSE: RVTY) is scheduled to release its financial results before the market opens on August 04. Analysts predict the company will report earnings of $1.16 per share, with revenue expectations around $677.67 million for the current fiscal quarter. These …

IQVIA Holdings (IQV) Earnings Beat Keeps Fair Value In Focus

IQVIA Holdings (IQV) reported strong Q2 results, exceeding analyst estimates and raising full-year guidance, leading to a significant 55.07% share price return over 90 days. Despite this positive momentum and a narrative-pegged fair value of $232 suggesting the stock is 4.7% overvalued at its …

CGON|CG Oncology Inc|Price:69.180|Chg%:-3.440

This article provides a comprehensive stock analysis of CG Oncology Inc (CGON) from TradingKey. The company's fundamentals are considered healthy with high growth potential, and its valuation is deemed fairly valued within the Biotechnology & Medical Research industry. Analysts have given a "Buy" rating …

Fulgent Genetics Inc (FLGT) Financial Health: Profitability & Balance Sheet Analysis

Fulgent Genetics Inc (FLGT) currently holds a financial score of 6.89, placing it 52nd out of 75 in the Healthcare Providers & Services industry, indicating stable financial health and high operating efficiency. Despite this, its latest quarterly revenue decreased by 3.16% year-over-year to $71.14M, …

AGL|agilon health inc|Price:92.730|Chg%:-6.410

This article provides a detailed stock analysis of agilon health inc (AGL), including real-time quotes, key financial figures, insights into its fundamentals and growth potential, and analyst ratings. It highlights that agilon health inc is a healthcare company focused on empowering primary care physicians …

Charles River Laboratories International Inc (CRL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Charles River Laboratories International Inc (CRL), noting its current valuation score and ranking within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio, comparing it to recent highs and lows, but states that …

MDxHealth SA (MDXH) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of MDxHealth SA (MDXH), covering its stock price, support and resistance levels, and various technical indicators and moving averages. As of July 29, 2026, MDXH has a price momentum score of 4.52 and is trading between a resistance …

VCYT|Veracyte Inc|Price:55.730|Chg%:+0.080

This article provides a comprehensive analysis of Veracyte Inc (VCYT), highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It details the company's diagnostic products for various cancers, institutional ownership, and analyst ratings, indicating a positive …

Charles River Laboratories International Inc. Stock Rises 7.2%, Outperforms Peers

Shares of Charles River Laboratories International Inc. (CRL) experienced a significant rise of 7.2% on Wednesday, outperforming its competitors. This strong performance indicates a positive market reaction to the company's recent activities or broader sector trends.

Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...

This article first appeared on GuruFocus. Total Revenue: $71.6 million, up 30% year-over-year. MRD Revenue: $66.2 million, up 33% year-over-year; core MRD revenue (excluding milestones) grew 49%. Clinical Revenue (MRD): Increased 53% year-over-year, driven by a 43% increase in testing volumes and a 7% …

ARVN|Arvinas Inc|Price:8.230|Chg%:+0.030

This article provides a comprehensive stock analysis of Arvinas Inc (ARVN), highlighting its healthy fundamentals, significant growth potential, and "fairly valued" status. It notes high institutional ownership and multiple "Buy" ratings from analysts, despite a medium-term expectation for the stock price to trend down …